Form 4: Tonix Pharmaceuticals Director, David L. Grange, Acquires 10,000 Stock Options

Director David L. Grange acquired 10,000 stock options in Tonix Pharmaceuticals Holding Corp. on May 13, 2025.

Summary

• On May 13, 2025, David L. Grange, a director of Tonix Pharmaceuticals Holding Corp., acquired 10,000 stock options.
• The options have an exercise price of $20.18.
• The options vest on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders and expire on May 13, 2035.
• Following the transaction, Mr. Grange directly owns 10,000 shares of Tonix Pharmaceuticals Holding Corp.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition by a director. While insider buying can be seen as positive, this is a grant of options, which is part of standard compensation.

Positives

• A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the options is tied to the Issuer's 2026 Annual Meeting of Stockholders.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• Shareholders may view the acquisition of stock options by a director as a sign of confidence in the company's future performance.

Key Dates

Keywords

stock options, Form 4, director, TNXP, Tonix Pharmaceuticals, insider trading